DDInter1254 DDInter899
Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.[label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen]. Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Nabumetone {u} (Compound) resembles {v} (Compound) Naproxen
Nabumetone {u} (Compound) resembles {v} (Compound) Melatonin
Nabumetone {u} (Compound) binds {v} (Gene) MPO
Nabumetone {u} (Compound) palliates {v} (Disease) osteoarthritis
Nabumetone {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nabumetone {u} (Compound) downregulates {v} (Gene) DNAJA3
Nabumetone {u} (Compound) causes {v} (Side Effect) Pruritus
Nabumetone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Nabumetone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Nabumetone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alteplase
Nabumetone (Compound) resembles Naproxen (Compound)
Nabumetone (Compound) resembles Melatonin (Compound)
Nabumetone (Compound) binds MPO (Gene)
Nabumetone (Compound) palliates osteoarthritis (Disease)
Nabumetone (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Nabumetone (Compound) downregulates DNAJA3 (Gene)
Nabumetone (Compound) causes Pruritus (Side Effect)
Nabumetone may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Alteplase